

AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
 Statement of unaudited financial results for the quarter ended 30 June 2021

Sl No.	Particulars	*Rs in lakhs except for earnings per share data			
		3 months ended 30/06/2021	Previous 3 months ended 31/03/2021	Corresponding 3 months ended in the previous year 30/06/2020	Year ended 31/03/2021
		Unaudited	Refer note 6	Unaudited	Audited
1	Revenue				
	a) Revenue from operations	17,540.20	21,025.71	19,357.76	81,358.38
	b) Other income	289.98	255.26	284.80	1,284.14
	Total income	17,830.18	21,280.97	19,622.56	82,642.52
2	Expenses				
	(a) Cost of materials consumed	1,767.95	2,622.86	2,085.38	9,725.78
	(b) Purchase of stock-in-trade	3,305.88	5,698.47	4,711.22	19,474.22
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,572.98	(669.52)	459.18	294.59
	(d) Employee benefits expense	5,479.34	5,249.64	5,634.75	21,954.39
	(e) Depreciation and impairment expense	476.08	584.19	456.16	2,012.59
	(f) Allowance for expected credit loss (net)	129.25	81.47	(17.92)	271.90
	(g) Selling, marketing and distribution expense	1,028.45	1,015.14	923.88	4,520.68
	(h) Other expenses	2,693.26	2,986.68	2,704.10	11,567.89
	(i) Finance cost	26.58	28.18	27.39	109.30
	Total expenses	18,479.78	17,597.11	16,984.12	89,931.14
3	Profit before exceptional and extraordinary items and tax (1-2)	1,350.40	3,683.86	2,638.44	12,709.38
4	Exceptional items	-	-	-	-
5	Profit before extraordinary items and tax (3+4)	1,350.40	3,683.86	2,638.44	12,709.38
8	Extraordinary items	-	-	-	-
7	Profit before tax (5+6)	1,350.40	3,683.86	2,638.44	12,709.38
8	Tax expense				
	- Current tax	416.65	854.87	859.54	3,482.78
	- Deferred tax	(90.58)	101.10	(84.56)	(103.75)
	Total tax expense	326.07	955.97	774.97	3,379.03
9	Profit after tax (7-8)	1,024.33	2,727.89	1,863.47	9,330.35
10	Other comprehensive income/(loss)				
	A. Items that will not be reclassified to profit or loss				
	Re-measurement gains/(losses) on post-employment benefit obligations	(12.32)	369.25	98.16	457.98
	Income tax effect on above	3.10	(92.83)	(24.71)	(115.26)
	Total other comprehensive income/ (loss), net of income tax	(9.22)	276.32	73.48	342.70
	Total comprehensive income for the period (9+10)	1,015.11	3,004.21	1,936.93	9,673.05
11	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00
12	Reserves (excluding revaluation reserves as per balance sheet)	0	-	-	45,117.28
13	Earnings per equity share of Rs 2/- each (basic and diluted)	4.10	10.91	7.46	37.32

J.S.



AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road,
Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2021

Notes:

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 3 The Company, which is in the business of manufacture and supply of essential goods, has been assessing the impact of the COVID-19 pandemic (including the second wave) on its business and believes that the pandemic does not have a material impact on the current or future operations, financial position and liquidity of the Company. Management has considered all significant possible impact of known events arising from the pandemic in the preparation of these financial results. Assessing the impact of COVID-19 is, however, a continuing process given the uncertainties associated with its nature and duration. The Company will continue to closely monitor any material changes to future economic conditions.
- 4 During the quarter, the Company received a demand notice for an amount of Rs.15,738.9 lakhs (and interest thereupon) under Trade Margin Rationalisation notification ("TMR notification") from National Pharmaceutical Pricing Authority (NPPA) alleging overcharging of a patented anti-cancer drug sold during the period of 8 March 2019 to 31 January 2021. The said drug has been included with certain other anti-cancer medicines, on which trade margin caps are applicable under TMR notification. Based on evaluation, Management is of the view that the TMR notification is not applicable to the aforesaid patented drug and all applicable laws relating to the pricing of the product have been complied with. The Company has filed a Writ Petition before the High Court of Delhi challenging the NPPA's demand notice. Based on assessment, supported by external legal advice, Management has concluded that it has a strong case and the Company can defend its position. Accordingly, no provision has been made in these financial results.
- 5 The Board of Directors, at its meeting dated 09 August 2021, has declared an interim dividend of Rs. 2/- per equity share aggregating to Rs 500.0/- lakhs
- 6 The figures for the quarter ended 31 March 2021 are the balancing figures between the audited figures in respect of the full financial year 31 March 2021 and the published unaudited year to date figures up to the third quarter of the respective financial year i.e., 31 December 2020 which were subjected to review by the statutory auditors.
- 7 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.
- 8 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 09 August 2021. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 June 2021.

V
Place: Bengaluru
Date: 09 August, 2021

**By Order of the Board of Directors
For AstraZeneca Pharma India Limited**


Gagandeep Singh Bedi
Managing Director

